Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032 | 16.91% CAGR Fuels Growth to USD 15.67 Billion as Gene Therapy and CDMO Demand Accelerate

globenewswire.com
AVIR Avid Bioservices, Inc. is listed as a company profile in the article, indicating its involvement in the viral vector and plasmid DNA manufacturing market. The article does not provide specific sentiment or performance data for the company. CAT Catalent, Inc. is mentioned in the company profiles section of the article, suggesting its participation in the viral vector and plasmid DNA manufacturing market. No specific sentiment or performance details are provided. CRL Charles River Laboratories International, Inc. is listed in the company profiles, indicating its presence in the viral vector and plasmid DNA manufacturing sector. The article does not offer specific sentiment or performance analysis for the company. DHR Cytiva, a subsidiary of Danaher Corporation, is mentioned in the company profiles. The article discusses the broader market for viral vector and plasmid DNA manufacturing, but provides no specific sentiment for Danaher. GEHC GE HealthCare Technologies, Inc. is listed in the company profiles section, indicating its involvement in the viral vector and plasmid DNA manufacturing market. The article does not provide specific sentiment or performance data for the company. REGN Genentech, Inc. is mentioned in the company profiles. While Genentech is a subsidiary of Roche, the article focuses on the viral vector and plasmid DNA manufacturing market and does not provide specific sentiment for Regeneron. MRK Merck KGaA is listed in the company profiles. The article discusses the viral vector and plasmid DNA manufacturing market, but does not provide specific sentiment or performance details for Merck & Co. RGEN Revvity, Inc. is listed in the company profiles. The article discusses the viral vector and plasmid DNA manufacturing market, but does not provide specific sentiment or performance details for Repligen. TMO Thermo Fisher Scientific Inc. is listed in the company profiles, indicating its involvement in the viral vector and plasmid DNA manufacturing market. The article does not provide specific sentiment or performance data for the company.

Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032 | 16.91% CAGR Fuels Growth to USD 15.67 Billion as Gene Therapy and CDMO Demand Accelerate Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The global viral vector and plasmid DNA manufacturing market is projected to reach USD 6.10 billion in 2026 and expand at a CAGR of 16.91% to USD 15.67 billion by 2032. The market research examines the manufacturing capacity, technologies, regional developments, competitive priorities, and investment opportunities shaping cell therapy, gene therapy, mRNA, vaccine, and genome-editing pipelines.

Market Overview

Demand is supported by approved adeno-associated virus (AAV), lentiviral, adenoviral, and plasmid-enabled products, alongside a growing clinical pipeline requiring scalable, GMP-compliant production. High-quality starting materials, validated analytics, batch consistency, and dependable supply remain critical industry requirements.

CDMOs and therapy developers are prioritizing shorter development timelines, flexible capacity, and integrated services covering:

The findings support strategic planning by clarifying where capacity constraints, technical requirements, and partnership opportunities are likely to influence clinical and commercial programs.

Transformative Manufacturing Shifts

Production is moving from artisanal, campaign-based models toward industrialized platforms incorporating closed processing, single-use bioreactors, automation, high-throughput analytics, and standardized quality systems. AAV and lentiviral vectors remain essential to in vivo gene therapy and ex vivo cell therapy, while plasmid DNA is increasingly important for viral vectors, mRNA templates, genome-editing tools, and DNA vaccines.

Large biopharmaceutical companies are balancing internal investments with CDMO partnerships to reduce supply risk. Emerging biotechnology companies continue to rely on external providers for speed, specialized expertise, and regulatory support. Competitive manufacturers are increasingly offering validated platforms that improve technology transfer, reduce comparability risk, and support programs from early clinical supply through commercialization.

Artificial Intelligence and Digitalization

AI is being applied to predictive bioreactor monitoring, accelerated design of experiments, chromatography optimization, anomaly detection, automated batch record review, and raw material variability assessment. Advanced analytics also strengthen the evaluation of potency, purity, and safety data.

AI-enabled digital twins can identify critical process parameters, anticipate yield variability, and reduce failed runs. Validated and explainable systems are gaining priority as manufacturers align digital capabilities with FDA, EMA, ICH, and PIC/S expectations. These insights enable decision-makers to evaluate digital investments that may improve manufacturing robustness while mitigating compliance and data-integrity risks.

Regional and Economic Group Insights

The G7 remains the leading demand and innovation bloc, while the European Union supports harmonized regulatory pathways and manufacturing modernization. BRICS, ASEAN, and GCC markets are becoming more relevant through biologics investment, clinical infrastructure, fill-finish capacity, and strategic manufacturing partnerships.

Country-Level Opportunities

The United States remains the primary commercial and regulatory reference market. The United Kingdom, Germany, France, Italy, and Spain offer strong research, GMP manufacturing, and treatment networks. China is scaling gene therapy and CDMO capabilities, India is strengthening cost-efficient biologics and plasmid production, and Japan and South Korea provide advanced regulatory and biomanufacturing environments.

Country comparisons provide a practical basis for market entry strategies, partnership selection, and geographic investment prioritization.

Actionable Priorities for Industry Leaders

Key Takeaways from This Report

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Viral Vector & Plasmid DNA Manufacturing Market, by Product Type

7.1. Introduction

7.2. Plasmid DNA

7.3. Viral Vector

7.3.1. Adeno-Associated Viral Vectors

7.3.2. Adenoviral Vectors

7.3.3. Herpes Simplex Virus (HSV) Vectors

7.3.4. Lentiviral Vectors

7.3.5. Retroviral Vectors

8. Viral Vector & Plasmid DNA Manufacturing Market, by Service Type

8.1. Introduction

8.2. Analytical Testing

8.3. Manufacturing

8.4. Process Development

8.4.1. Downstream Optimization

8.4.2. Formulation Development

8.4.3. Scale-Up/Technology Transfer

8.4.4. Upstream Optimization

8.5. Regulatory & CMC Support

9. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow Stage

9.1. Introduction

9.2. Downstream Processing

9.2.1. Capture

9.2.2. Clarification

9.2.3. Concentration/Buffer Exchange

9.2.4. Intermediate Purification

9.2.5. Polishing

9.3. Fill & Finish

9.4. Release & Stability Testing

9.5. Upstream Processing

9.5.1. Bioreactor Production

9.5.2. Cell Expansion

9.5.3. Transfection/Transduction

10. Viral Vector & Plasmid DNA Manufacturing Market, by Production Platform

10.1. Introduction

10.2. Bacterial

10.3. Cell-Free Systems

10.4. Insect

10.5. Mammalian

10.6. Yeast

11. Viral Vector & Plasmid DNA Manufacturing Market, by Bioprocess Mode

11.1. Introduction

11.2. Batch

11.3. Culture Format

11.3.1. Adherent

11.3.2. Suspension

11.4. Fed-Batch

11.5. Perfusion

12. Viral Vector & Plasmid DNA Manufacturing Market, by Source

12.1. Introduction

12.2. In-House Manufacturing

12.3. Outsourced/CDMO

13. Viral Vector & Plasmid DNA Manufacturing Market, by Application

13.1. Introduction

13.2. Cell Therapy

13.3. Gene Editing

13.4. Gene Therapy

13.5. Oncolytic Virotherapy

13.6. Research & Developement

13.7. Vaccine Development

14. Viral Vector & Plasmid DNA Manufacturing Market, by End User

14.1. Introduction

14.2. Biopharmaceutical Companies

14.3. Contract Development & Manufacturing Organizations (CDMOs)

14.4. Contract Research Organizations (CROs)

14.5. Research Institutions

15. Viral Vector & Plasmid DNA Manufacturing Market, by Disease Area

15.1. Introduction

15.2. Cardiovascular

15.3. Hepatic Diseases

15.4. Infectious Diseases

15.5. Metabolic/Endocrine

15.6. Musculoskeletal

15.7. Neurology

15.8. Oncology

15.9. Ophthalmology

15.10. Rare Genetic Disorders

16. Viral Vector & Plasmid DNA Manufacturing Market, by Region

16.1. Introduction

16.2. Asia-Pacific

16.3. North America

16.4. Latin America

16.5. Europe

16.6. Middle East

16.7. Africa

17. Viral Vector & Plasmid DNA Manufacturing Market, by Group

17.1. Introduction

17.2. ASEAN

17.3. GCC

17.4. European Union

17.5. BRICS

17.6. G7

17.7. NATO

18. Viral Vector & Plasmid DNA Manufacturing Market, by Country

18.1. Introduction

18.2. United States

18.3. Germany

18.4. China

18.5. United Kingdom

18.6. India

18.7. Japan

18.8. Russia

18.9. Brazil

18.10. Canada

18.11. Italy

18.12. Mexico

18.13. France

18.14. Spain

18.15. Australia

18.16. South Korea

19. Competitive Landscape

19.1. Market Share Analysis, 2025

19.2. Market Concentration Analysis, 2025

19.2.1. Concentration Ratio (CR)

19.2.2. Herfindahl Hirschman Index (HHI)

19.3. Recent Developments & Impact Analysis, 2025

19.4. Product Portfolio Analysis, 2025

19.5. Benchmarking Analysis, 2025

20. Company Profiles

20.1. Advanced BioScience Laboratories, Inc.

20.2. Akron Biotech

20.3. Aldevron, LLC

20.4. Avid Bioservices, Inc.

20.5. Batavia Biosciences B.V.

20.6. BioNTech IMFS GmbH

20.7. BioSpace, Inc.

20.8. Biovian Oy

20.9. c-LEcta GmbH

20.10. Catalent, Inc.

20.11. Charles River Laboratories International, Inc.

20.12. Creative Biogene

20.13. Cytiva by Danaher Corporation

20.14. FILTROX AG

20.15. Forge Biologics By Ajinomoto Co., Inc.

20.16. FUJIFILM Diosynth Biotechnologies Inc.

20.17. GE HealthCare Technologies, Inc.

20.18. Genentech, Inc.

20.19. GeneOne Life Science, Inc.

20.20. Genezen Laboratories, Inc.

20.21. GenScript Biotech Corporation

20.22. Hillgene Biopharma Co., Ltd.

20.23. Kaneka Eurogentec S.A.

20.24. Lonza Group Ltd.

20.25. Merck KGaA

20.26. Miltenyi Biotec B.V. & Co. KG

20.27. Oxford Biomedica plc

20.28. POLYPLUS TRANSFECTION S.A.

20.29. REGENXBIO Inc.

20.30. Revvity, Inc.

20.31. Takara Bio Inc.

20.32. Thermo Fisher Scientific Inc.

20.33. Twist Bioscience Corporation

20.34. uniQure N.V.

20.35. Wuxi AppTec Co., Ltd.

21. Key Experts

List of Figures [29]

List of Tables [331]

For more information about this report visit https://www.researchandmarkets.com/r/73v0gi

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.